Geron Corporation (NASDAQ:GERN) FDA Goes Slow With Imeteslat


Dallas, Texas 04/14/2014 (FINANCIALSTRENDS) –  Geron Corporation (NASDAQ:GERN) has several products which are known for their high efficacy has since found its earlier scorching pace of product development slowed down by the FDA.

Imetelsat has now been on partial hold

Geron Corporation (NASDAQ:GERN) had expected to see quick and fast growth of its key product- Imetelsat. FDA now has slowed the pace of trial for myelofibrosis, as it has adopted a watch and ward view that the drug could have toxic effects on the liver.

As per FDA directions, back in March, Geron cannot enrol new patients to the study. However, it will have to be noted that those patients who are currently under the treatment will now be able to receive treatment on a continual basis.

Incidentally, this is pursuant to the FDA call to curtail Phase 2 trials for two other cases thrombocythemia as well as myeloma.

Therefore, there were many hopes riding on myelofibrosis. However, the continued concerns about liver toxicity increasing, has temporarily led to this company losing out on much of the revenue.

Financial overview

Geron Corporation (NASDAQ:GERN) holds a market capital of$288.69 million. EPS is -0.30. Outstanding shares are 156.90 million. Beta 1.72. The stock opened at the previous trading session at $1.90. The stock has an infra-day trading range of $1.82 and $1.95. The 52 week trading range is $1.00 low, where the $7.79 is high.   The Profit to Earnings ratio is pending announcement.

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical which handles clinical stage product development. Its leading product is telomerase inhibitor. This product is typically used in treating ‘hematologic myeloiod malignancies.’ Based in California, this stock has been around in the beginning of 1990.

Geron Corporation (NASDAQ:GERN) has been providing cutting edge pharma solutions which bring out the various therapeutic solutions for multiple form malignancies.